Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.72 |
| ▸ | ACE2 | Q9BYF1 | 6/20 | 0.72 |
| ▸ | GZMB | P10144 | 14/20 | 0.72 |
| ▸ | MME | P08473 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22687186 | 1.00 | ACE (0.72) | ACEACE2GZMBMME | |
| SCHEMBL22687113 | 1.00 | ACE (0.72) | ACEACE2GZMBMME | |
| SCHEMBL22687303 | 0.94 | GZMB (0.73) | ACEACE2GZMBMME | |
| SCHEMBL22687276 | 0.92 | GZMB (0.71) | ACEACE2GZMBMME | |
| SCHEMBL22687099 | 0.92 | GZMB (0.73) | ACEACE2GZMBMME | |
| SCHEMBL22687250 | 0.91 | GZMB (0.75) | ACEACE2GZMBMME | |
| SCHEMBL22687277 | 0.91 | ACE (0.70) | ACEACE2GZMBMME | |
| SCHEMBL25354871 | 0.91 | GZMB (0.73) | ACEACE2GZMBMME | |
| SCHEMBL5917002 | 0.91 | GZMB (0.77) | ACEACE2GZMBMME | |
| SCHEMBL5917007 | 0.91 | GZMB (0.77) | ACEACE2GZMBMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-11667645-B2 | Granzyme B directed imaging and therapy | CYTOSITE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| CN-112261939-A | Granzyme B directed imaging and therapy | 塞托赛特生物制药股份有限公司 | 2021-01-22 | — | — | CN | disclosed |
| US-20200369673-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | ACE 1545/4885ACE2 1260/4885GZMB 1/4885 |
| US-20200369673-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | ACE 1545/4885ACE2 1260/4885GZMB 1/4885 |
| US-11667645-B2 | Granzyme B directed imaging and therapy | GZMB, PRF1, CTSB | ACE 1545/4885ACE2 1260/4885GZMB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.